Inhibitex will receiver over $4 million.

Inhibitex entered into a license and commercialization agreement with 3M for the development of various diagnostic products using Inhibitex’s MSCRAMM® protein platform. Under the terms of the agreement, Inhibitex granted 3M an exclusive global license to use Clumping Factor A (ClfA), an MSCRAMM protein, in the development of diagnostic products to detect Staphylococcus aureus and other bacterial and fungal pathogens.

Inhibitex will receive over $4 million over the next five years, including license fees, future milestone payments, financial support for further research and development activities, and royalty payments on product sales. 3M also received a license to use additional MSCRAMM protein targets for the development of other diagnostic products.
MSCRAMM proteins are a family of proteins located on the surface of pathogenic organisms.

Previous articleLannett Signs Agreement with PharmaSeed for Topical Pharma Drug
Next articleSeqWright to Perform Sequencing and Analysis for Third Wave HPV Trial